Advertisement
Advertisement
TVTX
Travere Therapeutics, Inc. Common Stock
42.59
USDSponsored
-1.51
-3.42%
May 15, 15:59 UTC -4
Closed
After-Market
42.58
-0.02
-0.04%
TVTX Earnings Reports
Positive Surprise Ratio
TVTX beat 17 of 42 last estimates.
40%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$163.46M
/-$0.12
Implied change from Q1 26 (Revenue/ EPS)
+28.51%
/-70.00%
Implied change from Q2 25 (Revenue/ EPS)
+42.82%
/-14.29%
Travere Therapeutics, Inc. Common Stock earnings per share and revenue
On May 04, 2026, TVTX reported earnings of -0.40 USD per share (EPS) for Q1 26, missing the estimate of -0.27 USD, resulting in a -47.66% surprise. Revenue reached 127.20 million, compared to an expected 139.01 million, with a -8.50% difference. The market reacted with a -0.24% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 11 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 163.46 million USD, implying an decrease of -70.00% EPS, and increase of 28.51% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$1.07
Actual
-$0.97
Surprise
+9.67%
Invivyd, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.13
Surprise
-73.80%
Autolus Therapeutics plc - ADR
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.26
Actual
-$0.27
Surprise
-2.94%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+217.65%
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
Elutia Inc. Class A Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
RenovoRx, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
Dare Bioscience, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.20
Surprise
+32.39%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
FAQ
What were Travere Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Travere Therapeutics, Inc. Common Stock reported EPS of -$0.40, missing estimates by -47.66%, and revenue of $127.20M, -8.5% below expectations.
How did the market react to Travere Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -0.24%, changed from $44.91 before the earnings release to $44.80 the day after.
When is Travere Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Travere Therapeutics, Inc. Common Stock's next earnings report?
Based on 11
analysts, Travere Therapeutics, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $163.46M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement